Bruker Corporation is a leading global provider of scientific instruments and analytical solutions, catering primarily to the life sciences, materials research, and industrial sectors. The company specializes in advanced technologies that facilitate research and development, including mass spectrometry, nuclear magnetic resonance, infrared spectroscopy, and X-ray diffraction. Bruker’s innovative products are essential for a wide range of applications, from drug discovery and environmental monitoring to quality control and materials characterization. Committed to enhancing scientific research and diagnostic capabilities, Bruker supports researchers and industries by delivering precise and reliable data for improved decision-making and insights. Read More
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Agilent (NYSE:A) and its peers.
Bruker Corporation (Nasdaq: BRKR) today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging at greater depths with 3D data reconstruction, providing researchers with unprecedented insights into neuronal activity. Featuring several innovations in miniscope design, nVista 2P offers enhanced resolution for sub-cellular imaging and mapping of neural circuit dynamics.
Bruker Corporation (NASDAQ: BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays.
Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company’s earlier outlook and well ahead of consensus.
At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, with new, research-use only NGS-based solutions in epidemiology and hospital acquired infection (HAI) tracing.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.
Let’s dig into the relative performance of Mettler-Toledo (NYSE:MTD) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season.
At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world’s first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. This first-of-a-kind ultra-high field magnet and spectrometer pushes the boundaries of what is possible in the field of NMR research and opens a new chapter of ultra-high field NMR with even higher dispersion and resolution.
At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration. This novel Fourier 80 ‘Multi-Talent’ system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with dramatically enhanced versatility in benchtop FT-NMR multinuclear analysis.
Bruker Corporation today announced the introduction of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop at the University of California San Francisco (UCSF) Hyperpolarized MRI Technology Resource Center. The first customer installation of this innovative technology has been successfully completed, marking a milestone in hyperpolarized MRI for preclinical research to improve cancer diagnostics and to assess response to treatment.
Shareholders of Bruker would probably like to forget the past six months even happened. The stock has dropped 39.9% and now trades at a new 52-week low of $41.52. This may have investors wondering how to approach the situation.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bruker (NASDAQ:BRKR) and its peers.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Danaher (NYSE:DHR) and the best and worst performers in the research tools & consumables industry.
Bruker Corporation (Nasdaq: BRKR) today announces the launch of the new X4 POSEIDON™, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). This innovative benchtop XRM system offers advanced capabilities comparable to larger, floor-standing systems to make high-resolution 3D X-ray microscopy accessible for demanding XRM applications in industrial applications and scientific research.
At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) announces significant advances in 4D-Proteomics™ performance, software and applications for deeper biological insights.
Bruker Corporation (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting. Bruker Spatial Biology will announce the following four innovations that underscore Bruker’s leading commitment to advancing spatial biology with pioneering, best-in-class platforms:
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker’s Audit Committee as a financial expert after Bruker’s annual shareholder meeting at the end of May 2025.
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025.
Scientific instrument company Bruker (NASDAQ:BRKR). reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 14.6% year on year to $979.6 million. On the other hand, the company’s full-year revenue guidance of $3.51 billion at the midpoint came in 1.8% below analysts’ estimates. Its non-GAAP profit of $0.76 per share was 3.2% above analysts’ consensus estimates.
